Skip to main content
. Author manuscript; available in PMC: 2014 Jan 29.
Published in final edited form as: J Immunol. 2010 Sep 15;185(8):4602–4608. doi: 10.4049/jimmunol.1001892

Figure 2. Conjugation of the TLR7 agonist to antigen does not increase antigen persistence in vivo.

Figure 2

Mice were injected subcuntaneously with 10 μg OVA alone, OVA mixed with the unconjugated TLR7 agonist or the OVA-TLR7a conjugate at 0, 1, 3, or 7 days prior to the intravenous transfer of CFSE-labeled TCR transgenic OTI T cells. Locally draining LNs were harvested 3 days following OTI T cell transfer, and the dilution of CFSE was assessed by gating on OTI T cells using SIINFEKL-H-2Kb Tetramer+ events. The data shown are representative of two independent experiments.